Navigation Links
ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
Date:4/16/2008

FREDERICK, Md., April 16 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the development of their lead anti-HIV therapeutic development candidate, IQP-0410, and lead topical microbicide development candidate, IQP-0528. ImQuest scientists Robert W. Buckheit, Jr., Ph.D. (Executive Vice President and Chief Scientific Officer) and Karen M. Watson, M.S. (Manager, Topical Microbicide Research & Development) were invited to speak at The International Conference on Antiviral Research (ICAR), being held this week in Montreal, Quebec, Canada. ImQuest studies have demonstrated that each of these highly novel pyrimidinedione inhibitors act by two distinct mechanisms of action, preventing the entry of HIV into human cells and inhibiting the activity of a key HIV enzyme, reverse transcriptase.

Dr. Buckheit presented detailed mechanism of action evaluations performed with IQP-0410, demonstrating that the compound targets a newly defined conformational cell surface target formed upon attachment of the virus to prevent the entry of HIV into the cells. This molecular target will be exploited by ImQuest to develop even more potent HIV entry inhibitors. Ms. Watson reported on results of preclinical efficacy and safety testing on the related pyrimidinedione microbicide, IQP-0528, to prevent the sexual transmission of HIV worldwide. The ImQuest team also demonstrated that IQP- 0410 was highly effective against multi-drug resistant HIV, especially viruses derived from patients treated extensively with protease inhibitors. The studies included ImQuest co-authors Lu Yang, M.D., Tracy Hartman, M.S., Christa E. Buckheit and Robert W. Buckheit, III.

"Our results clearly indicate that the pyrimidinediones represent a completely new class of HIV inhibitor that may be of great benefit to the prevention of HIV infection as a topical microbicide, the therapeutic treatment of primary HIV infection, as well as a salvage therapy for patients failing current drug regimens," said Dr. Buckheit. "We are excited that these molecules are rapidly progressing towards human clinical trials."

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry.

For further information regarding this press release please contact:

Robert W. Buckheit, Jr., Ph.D.

Executive Vice President and Chief Scientific Officer

ImQuest Life Sciences, Inc.

301-696-0274

rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
2. NovoCure presents results from breast cancer pilot study
3. Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment
4. Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008
5. 5W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation
6. CVS Caremark Presents at NCOA-ASA Conference on Companys Commitment to Recruiting and Retaining Mature Workers
7. RNR Public Relations Presents Perfect April Fools Day Feature Opportunity
8. New Jersey Hospital Association Presents Awards for Commitment to Healthcare
9. Brain stress system presents possible treatment
10. Joanne Steen Presents Grief Solutions at the Headquarters Marine Corps 2008 Casualty Conference
11. QueensLander Tours Presents an Adventure Boot Camp Cruise with John Spencer Ellis from Bravos The Real Housewives of Orange County
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... ... Viewers who like to educate themselves on current issues and who enjoy ... societal issues tend to appreciate and love the "Informed" series, hosted by Rob Lowe. ... for causes around the world. , Running for charity has become a ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ ... #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion with God. ... with God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “The Adventures of ... smart and silly dog who lives his life to the fullest, as God intended. ... published author Patti Holmgren, a mother and grandmother pursuing her passion for writing, especially ...
(Date:3/23/2017)... Alexandria, Virginia (PRWEB) , ... March 23, 2017 ... ... quality public health services to their communities, 16 more public health departments have ... This week’s decisions bring another 4.5 million people into the expanding network of ...
(Date:3/23/2017)... ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the contributions of those ... a significant impact on the careers of all others involved. , On Monday, ... into the MBI’s Hall of Fame. The induction took place during the World of ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017  Zymo Research Corp., also known ... Inc., who designs, manufactures and distributes liquid ... teams Zymo Research,s DNA methylation detection and ... products with Hamilton,s high-throughput automation platforms. Zymo ... microbiomics and RNA isolation for use on ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... A ReportsnReports.com report says, over the recent years, global ... sales of Adcetris and Kadcyla have been witnessing rapid growth after ... is driven by large number of ADC drugs in pipeline, rise ... ADCs. ... Tables and 94 Figures, 10 Major Company Profiles, spread across 154 ...
Breaking Medicine Technology: